Skip to main content
Skip to content
Case File
d-25035House Oversight

Ackrell Capital Cannabis Investment Report outlines FDA regulatory stance on THC/CBD foods and supplements

Other

The passage provides a summary of FDA guidance and regulatory framework for cannabis-derived products, but it contains no specific allegations, names, transactions, or actionable leads involving high‑ FDA guidance (Aug 2017) states THC/CBD cannot be added to foods sold interstate and are not dietary Regulatory ambiguity remains for hemp‑derived CBD products. DEA announced a policy to increase reg

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024712
Pages
1
Persons
0
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.